Multiple Myeloma | China In-Depth | China | 2023
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and immunomodulatory agents in China, the median overall survival (OS) has improved considerably in the last ten years. Moreover, this market is expected to expand further over the forecast period, fueled by the disease’s increasing incidence and the increasing uptake of targeted agents—most notably the upcoming bispecific antibodies (Janssen’s teclistamab and talquetamab, Pfizer’s elranatamab) and CAR-T cell therapies (Janssen’s cilta-cel, Carsgen’s CT053, Iaso’s CT103A)—owing to their potential efficacy in improving PFS in patients, especially in the relapsed/refractory setting. Despite the availability of several traditional and novel agents, there will remain a high unmet need for therapies that can significantly improve patients’ PFS and OS, representing an opportunity for new drug developers. In this report, we explore how unmet need, pricing, coverage, and regulatory reforms in the A&R landscape of China will likely impact the success of current and future players in this highly lucrative market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable multiple myeloma population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s multiple myeloma market and why?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of multiple myeloma in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for multiple myeloma in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release date
December 2023
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology
Diagnosed incidence of multiple myeloma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
FORECAST
Annualized, 10-year, drug-level sales and patient share of key multiple myeloma therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III / PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I products.
